Balchem Corporation's SVP and Chief R&D Officer Ren Anthony Gonzalez disclosed share holdings, revealing that most direct shares are restricted stock vesting over one to three years.
A Discounted Cash Flow analysis indicates Balchem Corporation is undervalued by roughly 25%, supported by $177.6 million in trailing twelve-month free cash flow. Capacity expansion offers upside, thou
Balchem Corp reported 18.70 billion MXN in annual revenue, with its Human Nutrition and Health segment contributing the majority at 11.89 billion MXN. The United States was the top regional market, ge
Balchem Corporation outlines strategies for manufacturers to meet rising protein demand in meat snacks, noting opportunities from GLP-1 trends and the use of MeatShure® microencapsulated acids.
H.C. Wainwright raised Balchem's price target to $215 following Q2 2026 results that exceeded revenue and earnings estimates, citing consistent growth and 16 consecutive years of dividend increases.
Balchem Corporation reported record quarterly revenue and adjusted EBITDA, yet its stock gained only 3% despite strong profitability trends. Analysts note the high 34.1x P/E ratio requires further eva
Balchem Corporation reported $1.04 billion USD in annual revenue, led by its Human Nutrition and Health segment. The United States contributed the majority of sales, totaling $759.45 million.
Various ETFs, including those from BlackRock and Vanguard, hold Balchem Corporation stock, primarily focusing on small-cap and extended market segments. The data includes financial metrics such as ass
Balchem Corp (BCPC) ranks 6th among 65 Chemicals companies with a financial score of 9.04, posting $270.71 million in quarterly revenue and an 8.72% year-over-year profit increase.
Balchem Corp shares traded near $162 with a slight decline, though analysts maintain a Buy rating with a target price of $200.75. The company is valued fairly within the Chemicals industry, supported
Balchem Corp ranks 28th in the Chemicals industry with a 7.00 institutional confidence score; institutional shareholding fell 4.74% QoQ to 88.34%, while top shareholder ETHSX increased its stake to 2.
Balchem Corp reported 822.23M CHF annual revenue, driven by its Human Nutrition and Health segment (522.74M CHF). The U.S. was the top geographic market, contributing 602.07M CHF.
Balchem Corporation published a detailed cash flow statement covering quarterly and annual periods, including operating, investing, and financing metrics. The report features an FAQ section explaining
Analysts project Balchem Corp (BCPC) to rank 33rd in the Chemicals industry with a $191.00 price target. Next-quarter revenue is expected at $268.50M with an EPS of $1.40.
Balchem Corporation amended its credit facility with JPMorgan, increasing revolving commitments to $650 million and extending maturity to 2031. The changes aim to improve liquidity and lower borrowing
TradingKey provides historical income statement data for Balchem Corp (BCPC) from FY2012Q1 through FY2026Q1, including revenue, expenses, and earnings per share metrics.
Balchem Corp shares rose 1.81% amid positive analyst sentiment, with reports citing strong fundamentals and high growth potential within the Chemicals industry. Analysts recommend a 'Buy' with a targe
Balchem Corporation generated 18.70 billion Mexican Pesos in total revenue last year, driven primarily by its Human Nutrition and Health segment. The United States remained the largest regional contri
The Vitamin K2 market is projected to reach USD 339.9 million by 2031, driven by demand for bone and cardiovascular health solutions. Key players include Gnosis by Lesaffre, Balchem Corp., and Novones
Balchem Corp ranks 62nd out of 65 in the Chemicals industry with a valuation score of 6.27 and a P/E ratio of 33.10, while other financial ratios remain undisclosed.
Argus Research has lowered its price target for Balchem Corporation (BCPC) to $148.00. The company develops and markets specialty performance ingredients for various industries.
Balchem Corporation missed Q3 2024 EPS and revenue expectations despite 4.35% year-over-year revenue growth, reporting actual EPS of $18.03 against consensus of $19.52.
Balchem renewed its partnership with Oregon State University's Linus Pauling Institute to advance education on iron nutrition and epigenetic health. The collaboration promotes Balchem's branded ingred
Balchem Corp (BX:BL9B) displays enterprise value to EBIT forward metrics on the BX Swiss exchange. Trading was closed at publication with no recorded trades.
Balchem Corporation renewed its partnership with Oregon State University's Linus Pauling Institute to expand education on iron nutrition and epigenetic health. The collaboration will enhance the Micro
Analysts forecast Balchem Corp (BL9B) stock prices ranging from 139.72 EUR to 199.35 EUR by 2027, citing recent earnings and revenue performance ahead of the July 24, 2026 report.
Balchem Corporation announced a second-quarter 2026 earnings conference call set for July 31, 2026. CEO Ted Harris and CFO Martin Bengtsson will lead the discussion following the pre-market release of
Balchem Corporation scheduled a conference call for July 31, 2026, to discuss second-quarter financial results, accessible via phone and webcast.
Balchem Corporation will release its second-quarter 2026 financial results before market open on July 31, accompanied by a live conference call at 11:00 AM ET for investors and analysts.
Balchem Corporation released new clinical research highlighting methylsulfonylmethane (MSM)'s efficacy in post-exercise recovery at a lower dose of 1 g/day. This finding offers significant formulation
Balchem Corporation joined several Russell value indices, increasing investor attention despite a high P/E ratio of 34.2x. While capacity expansion drives growth narratives suggesting undervaluation,
Balchem will showcase functional beverage and high-protein snack prototypes at IFT FIRST 2026, featuring technologies like Milk Protein Z-Crisps and MeatShure. These innovations aim to meet consumer d
Balchem Corporation will showcase better-for-you food and beverage concepts at IFT FIRST 2026, featuring new prototypes like Milk Protein Z-Crisps. The company aims to address consumer demand for well
A comprehensive list of Exchange Traded Funds (ETFs) holding Balchem Corp shares is provided, sorted by market value. This resource assists investors in identifying options for gaining exposure to the
Balchem Corporation has been added to multiple Russell indexes, increasing institutional visibility, while analysts emphasize its specialty nutrition portfolio and operational efficiency.
Balchem Corporation has been added to the Russell 2000 Value-Defensive Index, following its inclusion in other Russell benchmarks. The company manufactures performance ingredients for human nutrition,
TradingView displays Balchem Corp's forward Enterprise Value to EBITDA metric. The market was closed with no trades recorded at the time of publication.
Balchem Corp (BMV:BCPC) financial data highlights its enterprise value to forward revenue ratio on the Mexican Stock Exchange. Classified under Consumer Non-Durables in the Food: Specialty/Candy secto
This article details Balchem Corporation's financial actuals and estimates, including income statements, balance sheets, and cash flow data. It covers past earnings, revenue, dividends, and upcoming r
This article provides an overview of Balchem Corporation's stock performance, financial metrics, and analyst forecasts, including earnings, revenue, and market capitalization data.
Balchem Corporation announced its CEO and CFO will attend the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026, as part of investor outreach.
Balchem Corporation announced that key executives, including CEO Ted Harris, will participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026.
Overview of Balchem Corp stock performance, financial data, and analyst forecasts, including price history, market cap, earnings reports, and dividends.
Analysts forecast Balchem Corporation's stock price target for 2027, analyzing historical performance, earnings expectations, and dividend information.
Balchem Corporation stock trades at $169.23, with analysts projecting a fair value of $191 despite a high P/E ratio. Investors are advised to consider both upside potential and valuation risks.
Balchem invests $36M in Maryland microencapsulation facility for early 2026 Human Nutrition & Health operations. Q2 2025 results showed sales up 9% to $265M and net earnings rising 12%.
Balchem Corp reported an 8.06% revenue increase to $270.71M and an 8.72% net profit rise, maintaining a strong financial health score of 8.94 within the Chemicals industry.
Balchem Corp (BCPC) holds a valuation score of 6.21, ranking 65th among 68 Chemicals industry peers, with a P/E ratio of 33.66 while other metrics remain undisclosed.
Balchem shareholders elected two new directors and ratified an auditor during the annual meeting, following strong Q1 2026 financial results that beat market expectations.
Balchem Corporation filed a Form 8K with the SEC on June 22nd, per Investing.com. This regulatory filing serves as a standard disclosure event for the specialty ingredients manufacturer.
ChemBrief